Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. Company
    ADXN   CH0029850754

ADDEX THERAPEUTICS LTD

(ADXN)
  Report
Delayed Swiss Exchange  -  03:00 2022-12-05 am EST
0.1350 CHF   -0.88%
11/14Addex Therapeutics : INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K
PU
11/11Transcript : Addex Therapeutics Ltd, Q3 2022 Earnings Call, Nov 11, 2022
CI
11/11Addex Therapeutics Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Addex Therapeutics Ltd
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Number of employees : 28 people.
Sales per Business
20202021Delta
Small-molecule Pharmaceutical Products3.88100%3.15100% -18.71%
CHF in Million
Sales per region
20202021Delta
Switzerland0.27100%3.15100% +1084.01%
CHF in Million
Managers
Name Title Age Since
Timothy Dyer Chief Executive Officer 53 2013
Lénaic Teyssédou Head-Finance 35 2017
Roger G. Mills, Dr. Director & Chief Medical Officer 64 2017
Jean-Philippe Rocher, Dr. Head-Discovery Chemistry - -
Members of the board
Name Title Age Since
Vincent M. Lawton, Dr. Chairman 72 -
Jake R. Nunn Independent Director 50 2018
Isaac Manke, Dr. Independent Director 44 2018
Timothy Dyer Chief Executive Officer 53 2013
Raymond George Hill, Dr. Director 76 2015
Roger G. Mills, Dr. Director & Chief Medical Officer 64 2017
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 82,627,284 58,682,451 71.0% 12,114,608 14.7% 71.0%
Shareholders
NameEquities%
Addex Therapeutics Ltd 44,741,379 38.8%
Timothy Dyer 9,840,946 8.53%
NEA Management Co. LLC 5,648,690 4.90%
Caxton Corp. 2,314,489 2.01%
New Leaf Venture Partners LLC 1,647,444 1.43%
Credit Suisse Asset Management (Schweiz) AG 1,209,861 1.05%
Roger G. Mills 393,139 0.34%
UBS Asset Management Switzerland AG 159,250 0.14%
Herculis Partners SA 99,456 0.086%
BlackRock Asset Management Schweiz AG 44,784 0.039%
Holdings
NameEquities%Valuation
ADDEX THERAPEUTICS LTD (ADXN) 44,741,379 38.8% 6,259,319 USD
Company contact information
Addex Therapeutics Ltd.
9, Chemin des Aulx
Plan-les-Ouates
Geneva, Geneve (Geneva) 1202

Phone : +41.22.884.15.55
Fax : +41.22.884.15.56
Web : http://www.addextherapeutics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Addex Therapeutics Ltd
Sector Other Biotechnology & Medical Research